Literature DB >> 8580075

Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of PLP 95-116 as an HLA-DR2,w15-associated determinant.

T Ohashi1, T Yamamura, J Inobe, T Kondo, T Kunishita, T Tabira.   

Abstract

Multiple sclerosis (MS) is a putative autoimmune disease that is linked with HLA-DR2,w15. Proteolipid protein (PLP) is a candidate autoantigen in MS, but the disease-associated epitopes have not been determined. Using overlapping and non-overlapping PLP peptides, we have studied the T cell response to the major hydrophilic domain PLP 85-159 in the peripheral blood of MS and healthy subjects (HS). Short-term T cell lines (TCL) were selected against each peptide using microwell plates and the frequency of peptide-specific TCL was estimated. PLP 95-116-specific TCL were most efficiently generated and the frequency was significantly higher in MS compared with HS (P < 0.05). When compared between DR2,w15+ and DR2,w15- MS, TCL frequency to PLP 95-116 was significantly higher in DR2,w15+ MS (P < 0.005) and TCL reactive to the overlapping peptide 105-124 were also increased in DR2,w15+ MS (P < 0.025). Using DR gene-transfected L cells, we could show that the DRB1*1501 product of the DR2 haplotype presents PLP 95-116 to TCL selected against the peptide. These results imply that PLP 95-116 represents a major epitope for the DR2,w15+ MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580075     DOI: 10.1093/intimm/7.11.1771

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

Review 1.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

2.  Hla-DR2-restricted responses to proteolipid protein 95-116 peptide cause autoimmune encephalitis in transgenic mice.

Authors:  K Kawamura; T Yamamura; K Yokoyama; D H Chui; Y Fukui; T Sasazuki; H Inoko; C S David; T Tabira
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

Authors:  E A Elliott; H I McFarland; S H Nye; R Cofiell; T M Wilson; J A Wilkins; S P Squinto; L A Matis; J P Mueller
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

4.  T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired.

Authors:  Joan O'Keeffe; Carol M Gately; Timothy Counihan; Michael Hennessy; Teresa Leahy; Anthony P Moran; Edward L Hogan
Journal:  J Neurol Sci       Date:  2008-08-15       Impact factor: 3.181

5.  Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens.

Authors:  Ioana R Moldovan; Anne C Cotleur; Natacha Zamor; Robert S Butler; Clara M Pelfrey
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

6.  Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.

Authors:  M Krogsgaard; K W Wucherpfennig; B Cannella; B E Hansen; A Svejgaard; J Pyrdol; H Ditzel; C Raine; J Engberg; L Fugger; B Canella
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

Review 7.  Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis.

Authors:  Judith M Greer
Journal:  Mult Scler Int       Date:  2013-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.